

Hepatitis C Support Services for Patients and Providers

AcariaHealth is a national comprehensive specialty pharmacy focused on improving care and outcomes for patients living with complex and chronic conditions. We work closely with physician offices to support patients who are undergoing treatment for Hepatitis C. Our goal is to provide superior support to our providers and unrivaled care to our patients.

For Patients

We are a trusted resource for your patients and their caregivers, offering compassionate and personalized support including:

- > Convenient delivery to appropriate site of care, such as:



The Patient's Home



The Prescriber's Office

- > Welcome calls from our Clinical Care Team to answer questions about your medications, side effect management, etc.
- > Dedicated Hepatitis C Clinical Care Managers that guide patients throughout the treatment process
- > Detailed assistance with understanding insurance copays and accessing financial aid for treatment through manufacturer, government, and nonprofit-supported programs
- > Personalized engagement through ongoing phone calls and text alerts to remind patients of upcoming appointments, lab visits, scheduled refills, and medication shipments

For Health Care Providers

As part of our dedicated Hepatitis C Care Management Program, we collaborate with health care providers and become part of the care team. Our support includes:

- > Benefits investigation and prior authorization support during cycle of care including real-time referral status tracking, medical benefit investigation, and appeals process implementation
- > Adherence promotion through pharmacist-supported patient assessments and risk and side effect management, as well as nurse-supported therapy training
- > Patient drug utilization data collection and monitoring to document gaps in therapy for enhanced compliance and optimal treatment outcomes

Help us better serve your patients by including each of the checklist items below with every Hepatitis C prescription:

- > Patient demographic sheet and current insurance information. If not available, please inform the patient we will call them for their updated prescription coverage, or ask the patient to call AcariaHealth at 800.511.5144 to provide their prescription coverage information.
- > The patient's preferred contact number
- > Most recent clinical note that presents the patient's current situation. If previously treated, indicate when and what treatment was utilized.
- > Lab report with genotype
- > Lab report with CBC and CMP results
- > Lab report with recent viral load (HCV-RNA). Must be within 90 days.
- > Lab report with Fibrosis Score

Necessary lab reports can vary based on insurance requirements

**Contact us for additional
Hepatitis C pharmacist support**

Phone: 800.511.5144 ext. 6080033



Hepatitis C Product Guide

An Informational Guide for Providers and Physician Offices

Transforming Lives with Compassionate Care

AcariaHealth.com | @AcariaHealth

P: 800.511.5144

F: 877.541.1503

© 2024 AcariaHealth. All rights reserved. 240418

AcariaHealth
Specialty Pharmacy

AcariaHealth
Specialty Pharmacy

Hepatitis C Product Guide

Product Name	Epclusa	Mayvret	Vosevi	Harvoni
Generic	• Sofosbuvir 400mg / velpatasvir 100mg	• Glecaprevir 100mg / pibrentasvir 40mg	• Sofosbuvir 400mg / velpatasvir 100mg / voxilaprevir 100mg	• Ledipasvir 90mg /sofosbuvir 400mg
Indication(s)	<ul style="list-style-type: none"> For the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection: <ul style="list-style-type: none"> Without cirrhosis or with compensated cirrhosis With decompensated cirrhosis for use in combination with ribavirin 	<ul style="list-style-type: none"> For the treatment of adult and pediatric patients 3 years and older with: <ul style="list-style-type: none"> Chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both 	<ul style="list-style-type: none"> For the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis who have: <ul style="list-style-type: none"> Genotype 1,2,3,4,5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor Genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor 	<ul style="list-style-type: none"> For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: <ul style="list-style-type: none"> Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin
Manufacturer	• Gilead	• AbbVie	• Gilead	• Gilead
Dosage Form	• Oral tablets	• Oral tablets	• Oral tablets	• Oral tablets
Dosing	• Take one tablet by mouth, once daily, with or without food for treatment duration	• Take three tablets by mouth, once daily, with food for treatment duration	• Take one tablet by mouth, once daily, with food for treatment duration	• Take one tablet by mouth, once daily, with or without food for treatment duration
Storage	• Store at room temperature below 30°C (86°F), dispense only in original container	• Store at room temperature below 30°C (86°F)	• Store at room temperature below 30°C (86°F), dispense only in original container	• Store at room temperature below 30°C (86°F), dispense only in original container
Side Effects	• Most common side effects include headache and fatigue. When used with ribavirin, common side effects include fatigue, anemia, headache, insomnia, and diarrhea	• Most common side effects include headache and fatigue	• Most common side effects include headache, fatigue, diarrhea, and nausea	• Most common side effects include fatigue, headache, and asthenia
Drug Interactions	<ul style="list-style-type: none"> P-gp inducers and/or moderate to strong CYP inducers (e.g., rifampin, St. John’s wort, carbamazepine): May decrease concentrations of sofosbuvir and/or velpatasvir. Use of EPCLUSA with P-gp inducers and/or moderate to strong CYP inducers is not recommended Consult the full prescribing information prior to use for potential drug interactions Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary 	<ul style="list-style-type: none"> Carbamazepine, efavirenz, and St. John’s wort may decrease concentrations of glecaprevir and pibrentasvir. Coadministration of carbamazepine, efavirenz containing regimens, and St. John’s wort with MAVYRET is not recommended Consult the full prescribing information prior to and during treatment for potential drug interactions Clearance of HCV infection with direct-acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary 	<ul style="list-style-type: none"> P-gp inducers and/or moderate to strong CYP inducers (e.g., St. John’s wort, carbamazepine): May decrease concentrations of sofosbuvir, velpatasvir, and/or voxilaprevir. Use of VOSEVI with Pgp inducers and/or moderate to strong CYP inducers is not recommended Consult the full prescribing information prior to use for potential drug interactions Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary 	<ul style="list-style-type: none"> Coadministration with amiodarone may result in serious symptomatic bradycardia. Use of HARVONI with amiodarone is not recommended P-gp inducers (e.g., rifampin, St. John’s wort): May alter concentrations of ledipasvir and sofosbuvir. Use of HARVONI with P-gp inducers is not recommended Consult the full prescribing information prior to use for potential drug interactions Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary

DISCLAIMER: The information provided is a summary of available information only. This summary has been compiled by AcariaHealth and does not represent a clinical comparison conducted by any of the manufacturers referenced on any of these pages. It is to be used as a general reference tool only and is not intended for use as a guideline for clinical evaluations. The possibility of error (typographical or otherwise) exists in this summary. AcariaHealth expressly disclaims any and all warranties and liability arising out of or related to this information.